Patents by Inventor Lorraine Deck

Lorraine Deck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED THERANOSTICS FOR METASTATIC PROSTATE CANCER
    Publication number: 20140271470
    Abstract: The present invention relates to methods of diagnosing and treating prostate cancer, including metastatic prostate cancer. Related pharmaceutical compositions are also provided.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Laurel O. Sillerud, David L. Vander Jagt, Lorraine Deck
  • Therapeutic curcumin derivatives
    Publication number: 20070060644
    Abstract: Curcumin analogues and methods are provided for treatment of disease.
    Type: Application
    Filed: June 29, 2006
    Publication date: March 15, 2007
    Inventors: David Vander Jagt, Lorraine Deck, Steve Abcouwer, Robert Orlando, Robert Royer, Waylon Weber, Ekaterina Bobrovnikova-Marjon, Lucy Hunsaker
  • Cancer treatment using curcumin derivatives
    Publication number: 20060276536
    Abstract: Cancer or a precancerous condition is treated by administering a curcumin derivative to a subject.
    Type: Application
    Filed: March 10, 2006
    Publication date: December 7, 2006
    Inventors: David Vander Jagt, Lorraine Deck, Steve Abcouwer, Ekaterina Bobrovnikova-Marjon, Waylon Weber
  • Isocoumarin-based inhibitors of urokinase-type plasminogen activator
    Publication number: 20060252823
    Abstract: The present invention relates to chemical compounds, pharmaceutical compositions and methods for treating tumors and cancer and diseases which involve angiogenesis including retinopathy, age-related macular degeneration, angiogenic skin disorders and inflammation, including chronic inflammatory diseases, such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, arthritis, lupus and scleroderma, among others.
    Type: Application
    Filed: February 23, 2006
    Publication date: November 9, 2006
    Inventors: Lorraine Deck, David Vander Jagt, Justin Heynekamp
  • 11-Beta hydroxysteroid dehydrogenase type 1 inhibitors as anti-obesity/anti-diabetes compounds and 17-beta hydrosteroid dehydrogenase type I inhibitors as useful agents for the treatment of cancers, especially breast cancer
    Publication number: 20050228038
    Abstract: This invention is directed to the discovery that 11-Beta Hydroxysteroid Dehydrogenase Type 1 may be a common molecular etiology for visceral obesity and the metabolic syndrome of obesity as well a treatment for diabetes, especially type II diabetes. The present invention also relates to the use of certain compounds as inhibitors of 17-Beta Hydroxysteroid Dehydrogenase Type 1 and their use for the treatment of cancer, especially breast cancer.
    Type: Application
    Filed: March 30, 2005
    Publication date: October 13, 2005
    Inventors: David Vander Jagt, Robert Royer, Lorraine Deck
  • Inhibitors of cholesterol esterase
    Patent number: 6114545
    Abstract: The present invention provides novel haloenol lactones that are effective as active site inhibitors of cholesterol esterase. By inhibiting cholesterol esterase the inhibitors of the present invention provide a new approach to the treatment of hypercholesterolemia through limiting the bioavailability of dietary cholesterol.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: September 5, 2000
    Assignee: University of New Mexico
    Inventors: Lorraine Deck, David L. Vander Jagt
  • Inhibitors of cholesterol esterase
    Patent number: 6034255
    Abstract: The present invention provides novel haloenol lactones that are effective as active site inhibitors of cholesterol esterase. By inhibiting cholesterol esterase the inhibitors of the present invention provide a new approach to the treatment of hypercholesterolemia through limiting the bioavailability of dietary cholesterol.
    Type: Grant
    Filed: April 15, 1999
    Date of Patent: March 7, 2000
    Assignee: University of New Mexico
    Inventors: Lorraine Deck, David L. Vander Jagt
  • Inhibitors of cholesterol esterase
    Patent number: 5942631
    Abstract: The present invention provides novel haloenol lactones that are effective as active site inhibitors of cholesterol esterase. By inhibiting cholesterol esterase the inhibitors of the present invention provide a new approach to the treatment of hypercholesterolemia through limiting the bioavailability of dietary cholesterol.
    Type: Grant
    Filed: April 15, 1998
    Date of Patent: August 24, 1999
    Assignee: University Of New Mexico
    Inventors: Lorraine Deck, David L. Vander Jagt